Aristea Therapeutics

9:30 AM - 9:45 AM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases.

The Aristea team is leveraging its broad industry expertise and proven success in drug development to form synergistic partnerships and build a pipeline of novel drugs. Aristea’s lead program, RIST4721, is currently in Phase 2 clinical development for Palmoplantar Pustulosis (PPP), a rare neutrophil driven inflammatory skin disease for which there are no approved therapies in the the US or EU.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
RIST4721
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1